Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 12/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1863842 | 0.99 | SLC6A9 (0.45) | SLC6A9CYP3A4KCNH2SLC8A1HSD11B1 | |
| Hydrochloric Acid SCHEMBL1861717 | 0.89 | SLC6A9 (0.56) | SLC6A9CYP3A4KCNH2 | |
| SCHEMBL1859397 | 0.87 | SLC6A9 (0.40) | SLC6A9CYP3A4KCNH2HSD11B1NR1I2 | |
| SCHEMBL989592 | 0.85 | SLC6A9 (0.42) | SLC6A9CYP3A4HSD11B1 | |
| SCHEMBL1078429 | 0.85 | SLC6A9 (0.50) | SLC6A9CYP3A4KCNH2HSD11B1NR1I2 | |
| SCHEMBL1861599 | 0.85 | SLC6A9 (0.42) | SLC6A9CYP3A4KCNH2 | |
| SCHEMBL989558 | 0.84 | SLC6A9 (0.44) | SLC6A9CYP3A4 | |
| SCHEMBL990093 | 0.83 | MEN1 (0.48) | SLC6A9CYP3A4 | |
| SCHEMBL988888 | 0.83 | SLC6A9 (0.57) | SLC6A9CYP3A4KCNH2HSD11B1 | |
| Hydrochloric Acid SCHEMBL988292 | 0.82 | SLC6A9 (0.56) | SLC6A9CYP3A4KCNH2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott BmbH & Co. KG (DE) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105502-A1 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | GOLT1B, SLC10A1, SUGT1 | SLC6A9 73/4885CYP3A4 328/4885KCNH2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.